Effect of drug-coated balloons in treatment of stenosis of the femoral artery and vein bypass graft not responding to plain old balloon angioplasty: a case report

Sohei Matsuura, Kota Yamamoto, Takafumi Akai, Toshihiko Isaji, Toshio Takayama and Katsuyuki Hoshina*

Abstract

Background: The use of drug-coated balloons (DCBs) with anti-proliferative agents in treating femoropopliteal lesions was approved in Japan in 2017. A better limb salvage rate or amputation-free rate of DCBs relative to plain old balloon angioplasty (POBA) has been reported; however, there is little evidence of the direct effect on intimal hyperplasia (IH).

Case presentation: A 70-year-old man with chronic limb-threatening ischemia and foot gangrene had undergone bypass surgery from the left common femoral artery to the dorsalis pedis artery 2 years earlier. We evaluated the bypass graft using ultrasonography and found stenosis around the proximal anastomotic site, presumably due to IH. POBA was performed every 3 months due to the repeated re-stenosis of the lesion. Since using the DCB, no restenosis has been detected to date (10 months).

Conclusion: DCB might be an effective tool for treating re-stenosis due to IH or vein grafts that do not respond to POBA.

Keywords: Drug-coated balloon, Vein bypass graft, Restenosis, Plain old balloon angioplasty, Intimal hyperplasia

Introduction

Despite the remarkable advances in endovascular therapy, autogenous vein graft for peripheral arterial bypass remains the first choice for long occlusions or below-knee lesions due to its excellent patency [1, 2]. However, considering that approximately 30% of bypasses were reported to occlude within the first year after bypass surgery [3, 4], follow-up is critical for improving patency. In our department, we survey bypasses using duplex ultrasonography (DUS), which is noninvasive and low cost, every 3 months. We evaluate stenosis based on the elevation of the peak systolic velocity (PSV) of the artery or vein graft and consider a value of more than approximately 500 cm/s indication for re-intervention.

We have typically used plain old balloon angioplasty (POBA) for this re-intervention; however, we have sometimes encountered patients that were nonresponsive to POBA. The drug-coated balloon (DCB) has recently emerged and is expected to be a powerful tool in replacing POBA as it can achieve excellent outcomes, including increased limb salvage rate or amputation-free rate in the treatment of femoropopliteal lesions, which has recently been reported. However, there are only a few reports suggesting that DCB is beneficial for bypasses using autogenous grafts [5–8]. Among the various methods of improving the patency, the effect of anti-proliferative drugs on intimal hyperplasia (IH) of the anastomotic site is particularly attractive.

In this study, we report the case of a patient with chronic limb-threatening ischemia (CLTI) who underwent distal bypass, in which DCB was used in the treatment of repeated stenosis around the anastomotic site,

* Correspondence: traruba@gmail.com
Division of Vascular Surgery, Department of Surgery, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
presumably due to IH, and demonstrated the effect of
the DCB.

Case presentation
A 70-year-old man with CLTI and foot gangrene under-
went the bypass from the left common femoral artery to
the dorsalis pedis artery using a reversed saphenous vein
graft 2 years earlier (Fig. 1a). During DUS surveil-
ance, we initially found severe stenosis around the femoral
artery, anastomotic site, and vein bypass graft, where the
PSV was increased to 564 cm/s, and consequently
planned re-intervention (Fig. 1b). His medical history in-
cluded multiple coronary risk factors, including hyper-
tension, diabetes mellitus, and associated nephropathy
requiring hemodialysis, unstable angina, left thalamic
hemorrhage, and ex-smoker status. Above all, his cardiac
function had drastically deteriorated after repeated cor-
ony intervention performed for the unstable angina.
The ejection fraction finally decreased to below 20%,
which made it impossible to perform open surgery
under general anesthesia. We had no choice but to select
endovascular intervention (POBA) under local
anesthesia.

POBA
We performed a percutaneous puncture of the contralat-
eral common femoral artery and POBA under the guid-
ance of a 0.014-in. micro guide wire and 4.5-Fr guiding
sheath. The first time, we used a 1.5 × 20-mm Coyote Bal-
loon Dilation Catheter (Boston Scientific, Natick, MA,
USA) and 2.0 × 40-mm and 3.0 × 60-mm SABER PTA
dilatation catheters (Cordis, Santa Clara, CA, USA). The
second time after 111 days later, we used 2.0 × 40-mm and
3.0 × 40-mm SABER PTA dilatation catheters. The third
time after 115 days, we used 2.0 × 20-mm and 3.0 × 20-
mm Rapidstream balloon catheters (Nipro Corporation,
Osaka, Japan). In the final treatment using POBA after an-
other 67 days, we used a 2.5 × 40-mm SABER PTA dilata-
tion catheter and a 3.0 × 100-mm Rapidstream balloon
catheter. All POBA was performed under nominal recom-
manded pressure (8 atm for 3 mm). Dilatation was tem-
porarily achieved after each procedure.

DCB
We used a 4.0 × 60-mm IN.PACT Admiral DCB (Med-
tronic Vascular, Santa Clara, CA, USA), whose excipient
paclitaxel concentration was 3.5 μg/mm², after pre-

Fig. 1  a  Computed tomography angiography after distal bypass surgery. The reversed saphenous vein bypass is shown with a red bracket. The
proximal anastomotic site was focused in another window.  b  Intra-arterial digital angiography before percutaneous transluminal arterioplasty with
drug-coated balloons (DCBs). The stenosed area of the reversed saphenous vein graft is shown with a yellow bracket and the bypass graft is
shown with a red arrow.  c  Intra-arterial digital angiography after PTA with DCB. The stenotic lesion was successfully dilated using a DCB. Another
re-stenotic lesion was shown below without PSV increase, for which we diluted with DCB.
dilatation using 2.0 × 60-mm and 3.0 × 60-mm Rapid-stream balloon catheters (Fig. 1c). Because the 4.0 mm in diameter was oversized, we dilated the balloon to less than the nominal recommended pressure (8 atm), which approximated 2 or 3 atm. The range of the DCB covered the site which appeared slightly stenotic (Fig. 1c arrow) without increase of PSV via DUS.

Change of PSV
We had set the threshold for the PSV value at 500 cm/s for re-intervention after bypass surgery and regularly monitored the PSV in this patient. During the follow up period, PSV increased beyond 500 cm/s twice (659 and 563 cm/s, respectively) and we performed POBA both times. The third and fourth POBA procedures were performed on the stenosis with PSVs of 299 and 358 cm/s because the bypass pulsation was found to be weakened remarkably. Thereafter, we performed DCB on the stenosis, the fifth re-intervention, when the PSV reached 564 cm/s. After the procedure using DCB was performed 10 months earlier, no remarkable graft stenosis has been noted till date. (Fig. 2).

Discussion
DCB with anti-proliferation agents, such as paclitaxel or everolimus, was approved for femoropopliteal lesions in Japan in 2017 according to evidence from some randomized trials that demonstrated the superiority of DCBs over POBA in treatment [9–16]. However, the effect of DCBs on vein bypass grafts is controversial; Bjorkman et al. showed a trend in favor of DCBs in bypass grafts [5], but other reports did not demonstrate the superiority of DCBs over POBA [6–8]. As there are various causes of graft failure, these studies might lack the patient cohort volume to reveal a drug effect on IH. In our report, we focused on localized stenosis, presumably due to IH, and performed angioplasty on the same targeted lesion, which might make it possible to reveal the DCB effect more clearly.

Paclitaxel has multifunctional effects on IH and restenosis by inhibiting (1) proliferation of smooth muscle cells and fibroblasts, (2) migration of these cells, and (3) secretion of the extracellular matrix. Paclitaxel diffuses through the arterial wall to maintain high concentrations in the deeper smooth cells and fibroblast layers; however, it experiences quick wash-out from the luminal surface, which enables healing of endothelial cells [17]. These features of paclitaxel might cause a high anti-proliferating effect on IH and restenosis.

One limitation of this report was the difference in balloon diameter between the POBA and DCB. We had no choice but to select an oversized DCB due to a lack of device variation. It is therefore possible that our outcome comparison between DCB and POBA is biased relative to instructions for use.

The systematic review and meta-analysis reported by Katsanos et al. revealed that the risk of death was significantly increased after the first year following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg in patients with intermittent claudication [18]. It gave rise to heated discussion and an FDA statement required informed consent regarding the possibility of increased risk of long-term mortality when using paclitaxel-coated balloons and paclitaxel-eluting stents. In addition, the FDA warned that alternative treatment options for peripheral arterial disease should be discussed. However, they also stated that “for some individual patients at particularly high risk for restenosis, clinicians may determine that the benefits of using a paclitaxel-coated product may outweigh the risks [19].”

In our case, we explained the risks of long-term mortality according to the FDA statement and data from Katsanos et al.’s report and obtained informed consent. The patient expected the graft salvage not to lessen the activities of daily living. He found the need for repeated intervention during a short period of time tiring. We recognize that the merits and demerits of DCB offset each other. We assume that DCB for a localized lesion, theoretically associated with IH, may be acceptable.

Conclusion
We presented the case of a patient who underwent distal bypass and developed repeated stenosis over a short period around the anastomotic site, for which treatment with DCB was effective. DCB might be an effective tool in treating re-stenosis due to IH or vein grafts that do not respond to POBA.
Abbreviations
CLTI: Chronic limb-threatening ischemia; DCB: Drug-coated balloon; DUS: Duplex ultrasonography; IH: Intimal hyperplasia; POBA: Plain old balloon angioplasty; PSV: Peak systolic velocity

Acknowledgements
We would like to thank Editage (www.editage.jp) for English language editing.

Author’s contributions
SM and KY conceived of the case presentation. SM drafted the manuscript. TS, TA, TI, TT, and KH treated the patient. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
This study was approved by the ethical review board of the University of Tokyo (IRB No. 3316-41).

Consent for publication
The patient gave written informed consent for publication.

Competing interests
The authors declare that they have no competing interests.

Received: 5 November 2019 Accepted: 17 December 2019
Published online: 23 December 2019

References
1. Owens CD, Gasper WJ, Rahman A5, Conte MS, Francisco S. Vein graft failure. J Vasc Surg. 2015;61:203–16.
2. Saarinen E, Kauhanen P, Söderström M, Albäck A, Venermo M. Long-term results of inframalleolar bypass for critical limb ischaemia. Eur J Vasc Endovasc Surg. 2016;52:815–22.
3. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery; PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446–54.
4. Conte MS, Bandiky DF, Cloves AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–51 e1.
5. Björkman P, Kokkonen T, Alb A, Venermo M. Drug-coated versus plain balloon angioplasty in bypass vein grafts (the DRECOREST I-study). Ann Vasc Surg. 2019;55:36–44.
6. Kitrou P, Parthipun A, Diamantopoulos A, Padayachee S, Karunarithy N, Ahmed I, et al. Paclitaxel-coated balloons for failing peripheral bypass grafts: the BYPACS study. J Cardiovasc Surg. 2014;55:217–24.
7. Linni K, Ugurluoglu A, Aspalter M, Hitzl W, Hölzenbein T. Paclitaxel-coated versus plain balloon angioplasty in the treatment of infrainguinal vein bypass stenosis. J Vasc Surg. 2016;63:391–8.
8. Jongsma H, Akkersdijk GP, de Smet AAEA, Vroegindeweij D, de Vries J-PPM, Fioole B. Drug-eluting balloons and uncoated balloons perform equally to rescue infrainguinal autologous bypasses at risk. J Vasc Surg. 2017;66:454–60.
9. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the INPACT SFA randomized trial. Circulation. 2015;131(5):495–502.
10. Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of INPACT SFA. J Am Coll Cardiol. 2015;66;2529–38.
11. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53.
12. Scheinert D, Schulte K-L, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BOLLUX-P-I randomized trial. J Endovasc Ther. 2015;22:14–21.
13. Tepe G, Schnorr B, Albrecht T, Brechtle K, Claussen CD, Scheller B, et al. Angioplasty of femoropopliteal arteries with drug-coated balloons. JACC Cardiovasc Interv. 2015;8:102–8.
14. Schroeder H, Werner M, Meyer-D, Reimer P, Krüger K, Jaff MR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease. Circulation. 2017;135:227–36.
15. Krishnan P, Faries P, Niaz K, Jain A, Sachar R, Bachinsky WB, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease. Circulation. 2017;136:1102–13.
16. Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, et al. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 2019;93(4):664–72.
17. VG NG, Mena C, Petras C, Lansky A. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Eur J Clin Invest. 2015;45:333–45.
18. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
19. UPDATE: Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality - Letter to health care providers | FDA. https://www.fda.gov/medical-devices/letters-health-care-providers/update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting. Accessed 7 Aug 2019.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.